Massivemarkets

ANVS

Annovis Bio, Inc.

NYSE · usd

$0.9681-0.02 (-2.38%)
As of 11:41:19 AM EDT on Oct 23, 2026 · 15-minute delayed

Annovis Bio, Inc. (ANVS) trades at $0.9681 (-2.38%) as of 11:41:19 AM EDT on Oct 23, 2026, -27.21% over the past month. Market cap is $42.32M, with 6.0 days to cover in short interest.

Stock performance

How Annovis Bio, Inc. (ANVS) stock has performed from one day to one year, with its 52-week range.

-3.50%
-$0.04 over 1D
$0.96$0.97$0.99$1.007:00 AM10:00 AM10:30 AM11:10 AM11:40 AM$0.97
1D
-2.38%
1W
-2.55%
1M
-27.21%
YTD
-72.02%
1Y
-52.78%
52-wk range
$0.95 – $5.50

Key statistics

Today's trading snapshot for ANVS: day range, open, previous close, volume and market cap.

Day range
$0.96 – $1.00
Open
$0.99
Prev close
$0.99
Volume
173.09K
Market cap
$42.32M
Shares out
42.68M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Annovis Bio, Inc.: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
—
P/B
-9.93
P/FCF
—
ROE
1164.0%
ROA
-224.7%
Debt/Equity
0.00
Div yield
0.00%

As of Oct 22, 2026

8-K filings

Material corporate events Annovis Bio, Inc. has disclosed to the SEC on Form 8-K.

  • Shareholder meetingsJun 17, 2026

    On June 17, 2026, Annovis Bio, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") virtually. At the Annual Meeting, five proposals were submitted to the Company's stockholders and all matters voted upon were approved with the required votes.

  • Equity activityMay 20, 2026

    entered into an Underwriting Agreement (the "Underwriting Agreement"), dated as of May 20, 2026, with Canaccord Genuity LLC, as underwriter (the "Underwriter"), pursuant to which the Company agreed to issue and sell, in a public offering. The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company.

  • Equity activityApr 10, 2026

    On April 9, 2026, Annovis Bio, Inc. entered into an Underwriting Agreement with Canaccord Genuity LLC, as underwriter, pursuant to which the Company agreed to issue and sell, in an underwritten registered direct offering an aggregate of 5,263,156 shares of common stock and accompanying common stock warrants to purchase an aggregate of 5,263,156 shares of Common Stock. The combined offering price of each Share and accompanying Warrant is $1.90 per share. The gross proceeds to the Company from the Offering are expected to be approximately $10 million.

  • Investor communicationsJan 28, 2026

    On January 28, 2026, Annovis Bio, Inc. (the "Registrant") will conduct a webinar. A copy of the presentation for the webinar is furnished as Exhibit 99 hereto and incorporated herein by reference.

  • Equity activityOct 28, 2025

    the Company entered into (i) a Securities Purchase Agreement (the "Purchase Agreement"), with the purchasers signatory thereto (the "Purchasers") pursuant to which the Company agreed to issue and sell, in a registered direct offering (the "Offering") an aggregate of 597,561 shares of the Company's common stock... The offering price of each Share is $2.05 per share. The gross proceeds to the Company from the Offering are expected to be approximately $3.425 million, before deducting offering expenses payable by the Company.

ANVS short interest

How heavily ANVS is shorted: shares short, days to cover and average daily volume.

Days to cover
6.0
Short interest
5.9M
Avg volume
990.57K

As of · reported to FINRA twice monthly.

ANVS news

The latest news and headlines about Annovis Bio, Inc. (ANVS).

Frequently asked questions

What is the Annovis Bio, Inc. (ANVS) stock price today?

Annovis Bio, Inc. (ANVS) is trading at $0.9681 (-2.38% on the day) as of 11:41:19 AM EDT on Oct 23, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Annovis Bio, Inc.?

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia.

What is the short interest in ANVS?

As of Sep 30, 2026, ANVS has 5.9M shares short and 6.0 days to cover.

What exchange is ANVS listed on?

Annovis Bio, Inc. (ANVS) trades on NYSE in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of ANVS with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ANVS analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Want the most up-to-date, real-time data? Connect to the Massive API and MCP server — the source behind every number on this page — covering stocks, options, indices, currencies and futures. Docs: https://massive.com/docs/rest. Get a free API key.

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.